CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SPTLC1 (ImmuneEditome ID:10558)

1. Gene summary of enriched editing regions for SPTLC1

check button Gene summary
Gene informationGene symbol

SPTLC1

Gene ID

10558

GeneSynonymsALS27|HSAN1|HSN1|LBC1|LCB1|SPT1|SPTI
GeneCytomap

9q22.31

GeneTypeprotein-coding
GeneDescriptionserine palmitoyltransferase 1|long chain base biosynthesis protein 1|serine C-palmitoyltransferase|serine-palmitoyl-CoA transferase 1
GeneModificationdate20230403
UniprotIDA0A8I5QJP4;O15269;A0A2R8Y763;A0A8I5KUM4;A0A2R8Y6A2;A0A8I5KWE0;A0A8I5QKQ8;A0A024R277;A0A2R8Y4S0
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr9:92032718-92033838:-ENST00000469778.1ENSG00000090054.12SPTLC1ncRNA_intronicAluJb,MER58A,L2c,AluYchr9:92032718-92033838:-.alignment
chr9:92078561-92079375:-ENST00000482632.4ENSG00000090054.12SPTLC1ncRNA_intronicAluJb,AluSx1chr9:92078561-92079375:-.alignment


Top

2. Tumor-specific enriched editing regions for SPTLC1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr9:92078561-92079375:-SKCMEER8.3904e-042.2753e-033.1727e+01image
ENSG00000090054.12,SPTLC1SKCMEAG8.3904e-042.2753e-033.1727e+01image

Top

3. Enriched editing regions and immune related genes for SPTLC1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr9:92078561-92079375:-GBMEERENSG00000007516,BAIAP30.30782.4807e-023.0227e-060.4099imageNELAVL1NAGSVA_HALLMARK_MYC_TARGETS_V1
chr9:92078561-92079375:-TGCTEERENSG00000165704,HPRT1-0.58967.1694e-081.5104e-08-0.5056imageNELAVL1;MSI1HPRT1NK_cells_activatedGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr9:92078561-92079375:-TGCTEERENSG00000130147,SH3BP40.55495.6056e-076.9925e-090.5156imageNELAVL1;MSI1SH3BP4B_cells_naiveGSVA_HALLMARK_P53_PATHWAY
chr9:92078561-92079375:-TGCTEERENSG00000105514,RAB3D0.53022.8250e-063.1135e-070.4630imageNELAVL1RAB3DB_cells_naiveGSVA_HALLMARK_P53_PATHWAY
chr9:92078561-92079375:-TGCTEERENSG00000142149,HUNK0.50945.5093e-061.2496e-070.4765imageNELAVL1NAB_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
chr9:92078561-92079375:-TGCTEERENSG00000139645,ANKRD520.49666.7805e-061.4824e-060.4385imageNELAVL1;MSI1NAB_cells_naiveGSVA_HALLMARK_P53_PATHWAY
chr9:92078561-92079375:-TGCTEERENSG00000162430,SEPN10.49131.3254e-057.3923e-080.4840imageNELAVL1;MSI1NAB_cells_naiveGSVA_HALLMARK_P53_PATHWAY
chr9:92078561-92079375:-TGCTEERENSG00000071051,NCK20.48021.3575e-054.2292e-070.4583imageNELAVL1;MSI1NCK2B_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr9:92078561-92079375:-TGCTEERENSG00000104723,TUSC30.49231.4407e-051.0577e-080.5103imageNELAVL1;MSI1NAB_cells_naiveGSVA_HALLMARK_P53_PATHWAY
chr9:92078561-92079375:-TGCTEERENSG00000179833,SERTAD20.48381.8795e-059.0657e-070.4464imageNELAVL1;MSI1NAB_cells_naiveGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

4. Enriched editing regions and immune related splicing for SPTLC1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000090054.12,SPTLC1
ESCAEAGA3ENSG00000167658.11chr193979328:3979436:3977891:3978007:3977891:3978091-0.22763.4512e-022.4822e-05-0.4161imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RC3H1;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NA
ENSG00000090054.12,SPTLC1
GBMEAGIRENSG00000102144.9chrX78124873:78125011:78125326:78125425-0.12062.6136e-021.7298e-06-0.4190imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAEosinophils
chr9:92078561-92079375:-
GBMEERIRENSG00000102144.9chrX78124873:78125011:78125326:78125425-0.12052.2473e-021.8387e-06-0.4180imageNELAVL1;MSI1NAEosinophils
chr9:92078561-92079375:-
TGCTEERESENSG00000029725.12chr175354400:5354490:5356507:5356573:5361207:53614380.34321.1165e-023.2052e-050.4012imageNELAVL1;MSI1RABEP1B_cells_naiveGSVA_HALLMARK_NOTCH_SIGNALING
ENSG00000090054.12,SPTLC1
TGCTEAGIRENSG00000100890.11chr1435122562:35122635:35122951:35124231-0.34656.1015e-033.1279e-05-0.4218imageNACIN1;ADAR;ALYREF;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LARP7;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;SF3A3;SF3B4;SMNDC1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000090054.12,SPTLC1
TGCTEAGIRENSG00000089006.12chr2017968374:17968457:17968699:179689800.43208.6669e-047.5690e-070.4511imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NANK_cells_activatedGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000090054.12,SPTLC1
TGCTEAGIRENSG00000215193.8chr2218077922:18078047:18078295:180786060.34269.1046e-031.1143e-050.4258imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr9:92078561-92079375:-
TGCTEERIRENSG00000100890.11chr1435122562:35122635:35122951:35124231-0.34997.3185e-034.2856e-05-0.4217imageNELAVL1;MSI1NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
chr9:92078561-92079375:-
TGCTEERIRENSG00000073712.9chr1452881035:52881138:52881243:52881363-0.30761.0105e-026.3523e-05-0.4005imageNELAVL1;MSI1FERMT2NK_cells_activatedGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
ENSG00000090054.12,SPTLC1
TGCTEAGIRENSG00000066923.13chr7100211010:100211185:100211434:1002115390.36717.1577e-031.5809e-050.4114imageNACIN1;ADAR;CELF2;DGCR8;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;KHSRP;LIN28B;LSM11;PRPF8;PTBP1;RBFOX2;RBM10;SF3A3;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;TAF15;TARBP2;TARDBP;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1NAT_cells_CD4_memory_restingGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

More results



Top

5. Enriched editing regions and immune infiltration for SPTLC1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr9:92078561-92079375:-CESCEERMonocytes3.6547e-02-0.1506image
ENSG00000090054.12,SPTLC1CESCEAGMonocytes3.7392e-02-0.1496image
chr9:92078561-92079375:-COADEERNeutrophils1.5276e-020.2362image
chr9:92078561-92079375:-GBMEERNK_cells_resting4.1662e-030.2587image
ENSG00000090054.12,SPTLC1GBMEAGNK_cells_resting3.6166e-030.2626image
chr9:92078561-92079375:-HNSCEERPlasma_cells3.7167e-03-0.1687image
ENSG00000090054.12,SPTLC1HNSCEAGPlasma_cells2.6277e-03-0.1740image
ENSG00000090054.12,SPTLC1KICHEAGT_cells_CD83.2504e-02-0.3622image
ENSG00000090054.12,SPTLC1KIRCEAGMacrophages_M22.4623e-02-0.1708image
chr9:92078561-92079375:-KIRPEERNeutrophils2.5109e-020.2116image
ENSG00000090054.12,SPTLC1KIRPEAGNeutrophils4.5683e-020.1876image
chr9:92078561-92079375:-LGGEERT_cells_CD4_memory_resting2.8765e-02-0.1412image
ENSG00000090054.12,SPTLC1LGGEAGT_cells_CD4_memory_resting2.9596e-02-0.1399image
chr9:92078561-92079375:-LIHCEEREosinophils4.4462e-02-0.1572image
ENSG00000090054.12,SPTLC1LIHCEAGEosinophils4.4462e-02-0.1572image
ENSG00000090054.12,SPTLC1LUADEAGNeutrophils2.2083e-03-0.2111image
chr9:92078561-92079375:-LUSCEERMonocytes2.5842e-02-0.1330image
ENSG00000090054.12,SPTLC1LUSCEAGMonocytes2.2925e-02-0.1357image
chr9:92078561-92079375:-MESOEERT_cells_gamma_delta3.8180e-020.2883image
ENSG00000090054.12,SPTLC1MESOEAGT_cells_gamma_delta3.8180e-020.2883image
ENSG00000090054.12,SPTLC1OVEAGNK_cells_activated4.3581e-020.1391image
chr9:92078561-92079375:-PAADEERB_cells_naive2.3770e-02-0.2155image
ENSG00000090054.12,SPTLC1PAADEAGB_cells_naive1.0192e-02-0.2440image
chr9:92078561-92079375:-PRADEERT_cells_CD4_memory_resting4.6995e-020.1098image
ENSG00000090054.12,SPTLC1READEAGT_cells_regulatory_(Tregs)3.9833e-030.3927image
chr9:92078561-92079375:-SARCEERT_cells_CD4_memory_resting1.5835e-020.1870image
ENSG00000090054.12,SPTLC1SARCEAGT_cells_CD4_memory_resting1.6807e-020.1843image
chr9:92078561-92079375:-SKCMEERT_cells_CD87.0096e-030.1851image
ENSG00000090054.12,SPTLC1SKCMEAGT_cells_CD89.2062e-030.1785image
chr9:92078561-92079375:-TGCTEERMast_cells_resting7.6399e-03-0.2520image
ENSG00000090054.12,SPTLC1TGCTEAGNK_cells_activated9.7285e-03-0.2412image
ENSG00000090054.12,SPTLC1THYMEAGMast_cells_resting3.4581e-030.3357image
ENSG00000090054.12,SPTLC1UCECEAGT_cells_gamma_delta3.7655e-020.2114image
ENSG00000090054.12,SPTLC1UCSEAGNeutrophils2.6419e-020.3750image
ENSG00000090054.12,SPTLC1UVMEAGT_cells_CD4_memory_resting2.7349e-020.4325image


Top

6. Enriched editing regions and immune gene sets for SPTLC1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr9:92078561-92079375:-HNSCEER1.0142e-03image2.1863e-020.1337image
ENSG00000090054.12,SPTLC1HNSCEAG1.3001e-03image2.4044e-020.1309image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000090054.12,SPTLC1ACCGSVA_HALLMARK_UV_RESPONSE_UPEAG7.9130e-04-0.4552image
chr9:92078561-92079375:-ACCGSVA_HALLMARK_UV_RESPONSE_UPEER7.9130e-04-0.4552image
ENSG00000090054.12,SPTLC1BLCAGSVA_HALLMARK_NOTCH_SIGNALINGEAG3.7199e-02-0.1346image
ENSG00000090054.12,SPTLC1BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.6015e-030.1104image
chr9:92078561-92079375:-BRCAGSVA_HALLMARK_PROTEIN_SECRETIONEER4.0132e-030.1130image
ENSG00000090054.12,SPTLC1CESCGSVA_HALLMARK_P53_PATHWAYEAG5.1851e-04-0.2469image
chr9:92078561-92079375:-CESCGSVA_HALLMARK_P53_PATHWAYEER3.5194e-04-0.2546image
ENSG00000090054.12,SPTLC1COADGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG2.0189e-040.3503image
chr9:92078561-92079375:-COADGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER2.5664e-050.3984image
chr9:92078561-92079375:-ESCAGSVA_HALLMARK_MTORC1_SIGNALINGEER4.7416e-02-0.1729image
chr9:92078561-92079375:-GBMGSVA_HALLMARK_ANDROGEN_RESPONSEEER4.0555e-03-0.2595image
ENSG00000090054.12,SPTLC1GBMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG5.1200e-03-0.2530image
ENSG00000090054.12,SPTLC1HNSCGSVA_HALLMARK_UV_RESPONSE_DNEAG1.0309e-030.1895image
chr9:92078561-92079375:-HNSCGSVA_HALLMARK_UV_RESPONSE_DNEER8.9170e-040.1928image
ENSG00000090054.12,SPTLC1KICHGSVA_HALLMARK_MYOGENESISEAG5.1038e-03-0.4629image
ENSG00000090054.12,SPTLC1KIRCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG2.1289e-02-0.1750image
chr9:92078561-92079375:-LGGGSVA_HALLMARK_APICAL_JUNCTIONEER1.8439e-03-0.2000image
ENSG00000090054.12,SPTLC1LGGGSVA_HALLMARK_APICAL_JUNCTIONEAG1.6224e-03-0.2016image
chr9:92078561-92079375:-LIHCGSVA_HALLMARK_UV_RESPONSE_DNEER2.8260e-030.2318image
ENSG00000090054.12,SPTLC1LIHCGSVA_HALLMARK_UV_RESPONSE_DNEAG2.8260e-030.2318image
ENSG00000090054.12,SPTLC1LUADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.8945e-020.1367image
chr9:92078561-92079375:-MESOGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.2907e-02-0.2964image
ENSG00000090054.12,SPTLC1MESOGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG3.2907e-02-0.2964image
ENSG00000090054.12,SPTLC1OVGSVA_HALLMARK_MYC_TARGETS_V1EAG4.9072e-020.1357image
ENSG00000090054.12,SPTLC1PCPGGSVA_HALLMARK_G2M_CHECKPOINTEAG3.5026e-020.1837image
chr9:92078561-92079375:-PCPGGSVA_HALLMARK_G2M_CHECKPOINTEER3.3750e-020.1850image
ENSG00000090054.12,SPTLC1PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG3.2883e-02-0.1178image
chr9:92078561-92079375:-PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEER3.5481e-02-0.1162image
ENSG00000090054.12,SPTLC1READGSVA_HALLMARK_E2F_TARGETSEAG1.6409e-02-0.3314image
ENSG00000090054.12,SPTLC1SARCGSVA_HALLMARK_GLYCOLYSISEAG4.8030e-03-0.2166image
chr9:92078561-92079375:-SARCGSVA_HALLMARK_GLYCOLYSISEER4.5588e-03-0.2191image
chr9:92078561-92079375:-SKCMGSVA_HALLMARK_KRAS_SIGNALING_UPEER9.5199e-03-0.1781image
ENSG00000090054.12,SPTLC1SKCMGSVA_HALLMARK_KRAS_SIGNALING_UPEAG6.9116e-03-0.1850image
ENSG00000090054.12,SPTLC1STADGSVA_HALLMARK_SPERMATOGENESISEAG3.7905e-02-0.1335image
ENSG00000090054.12,SPTLC1TGCTGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.8240e-03-0.2889image
chr9:92078561-92079375:-TGCTGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.0699e-03-0.3065image
ENSG00000090054.12,SPTLC1THCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.2000e-04-0.1884image
chr9:92078561-92079375:-THCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.0286e-04-0.1902image
ENSG00000090054.12,SPTLC1THYMGSVA_HALLMARK_P53_PATHWAYEAG3.9042e-030.3316image
ENSG00000090054.12,SPTLC1UCECGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.2137e-02-0.2538image
chr9:92078561-92079375:-UCECGSVA_HALLMARK_PROTEIN_SECRETIONEER1.0745e-02-0.2593image
ENSG00000090054.12,SPTLC1UCSGSVA_HALLMARK_PEROXISOMEEAG4.3391e-020.3434image
ENSG00000090054.12,SPTLC1UVMGSVA_HALLMARK_MYC_TARGETS_V2EAG4.1785e-03-0.5427image


Top

7. Enriched editing regions and drugs for SPTLC1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000090054.12,SPTLC1ACCGSK.650394EAG6.3356e-050.5300image
chr9:92078561-92079375:-ACCGSK.650394EER6.3356e-050.5300image
ENSG00000090054.12,SPTLC1BLCACMKEAG1.3527e-020.1592image
chr9:92078561-92079375:-BRCABryostatin.1EER4.5876e-030.1114image
ENSG00000090054.12,SPTLC1BRCACHIR.99021EAG7.0627e-030.1050image
chr9:92078561-92079375:-CESCCGP.082996EER3.6338e-050.2926image
ENSG00000090054.12,SPTLC1CESCCGP.082996EAG5.3232e-050.2859image
ENSG00000090054.12,SPTLC1COADBIRB.0796EAG6.5952e-030.2599image
chr9:92078561-92079375:-COADBIRB.0796EER5.1322e-030.2712image
chr9:92078561-92079375:-ESCAA.443654EER3.6714e-030.2512image
ENSG00000090054.12,SPTLC1ESCALenalidomideEAG9.7338e-03-0.2218image
chr9:92078561-92079375:-GBMAUY922EER1.3402e-020.2243image
ENSG00000090054.12,SPTLC1GBMAUY922EAG1.2589e-020.2262image
ENSG00000090054.12,SPTLC1HNSCA.443654EAG5.1211e-040.2004image
chr9:92078561-92079375:-HNSCA.443654EER1.0912e-030.1896image
ENSG00000090054.12,SPTLC1KICHEtoposideEAG5.1660e-030.4624image
ENSG00000090054.12,SPTLC1KIRCMG.132EAG1.0249e-030.2476image
chr9:92078561-92079375:-KIRPJNJ.26854165EER2.0489e-05-0.3908image
ENSG00000090054.12,SPTLC1KIRPJNJ.26854165EAG4.5491e-05-0.3722image
chr9:92078561-92079375:-LGGA.443654EER1.4752e-020.1572image
ENSG00000090054.12,SPTLC1LGGA.443654EAG1.2925e-020.1596image
ENSG00000090054.12,SPTLC1LIHCCamptothecinEAG2.6616e-030.2331image
chr9:92078561-92079375:-LIHCCamptothecinEER2.6616e-030.2331image
ENSG00000090054.12,SPTLC1LUADABT.888EAG2.5003e-02-0.1554image
chr9:92078561-92079375:-LUSCCyclopamineEER2.8962e-04-0.2146image
ENSG00000090054.12,SPTLC1LUSCCyclopamineEAG2.0317e-04-0.2199image
ENSG00000090054.12,SPTLC1OVCEP.701EAG1.1342e-03-0.2226image
chr9:92078561-92079375:-PAADBIRB.0796EER4.6283e-02-0.1904image
chr9:92078561-92079375:-PCPGEHT.1864EER1.7549e-020.2064image
ENSG00000090054.12,SPTLC1PCPGEHT.1864EAG1.7886e-020.2058image
ENSG00000090054.12,SPTLC1PRADLenalidomideEAG7.7460e-03-0.1468image
chr9:92078561-92079375:-PRADLenalidomideEER1.3372e-02-0.1365image
ENSG00000090054.12,SPTLC1READGW843682XEAG1.4607e-020.3369image
chr9:92078561-92079375:-SARCBMS.509744EER2.6001e-040.2799image
ENSG00000090054.12,SPTLC1SARCBMS.509744EAG2.1845e-040.2815image
chr9:92078561-92079375:-SKCMJNK.9LEER5.3651e-03-0.1910image
ENSG00000090054.12,SPTLC1SKCMJNK.9LEAG4.8590e-03-0.1927image
ENSG00000090054.12,SPTLC1STADBIRB.0796EAG1.2019e-03-0.2070image
chr9:92078561-92079375:-TGCTAMG.706EER4.8851e-040.3256image
ENSG00000090054.12,SPTLC1TGCTAMG.706EAG4.3035e-040.3244image
ENSG00000090054.12,SPTLC1THCALenalidomideEAG5.9924e-03-0.1352image
chr9:92078561-92079375:-THCALenalidomideEER7.3211e-03-0.1320image
ENSG00000090054.12,SPTLC1THYMBicalutamideEAG1.4249e-02-0.2839image
chr9:92078561-92079375:-UCECAZD6244EER7.3579e-03-0.2733image
ENSG00000090054.12,SPTLC1UCECAZD6244EAG1.8789e-02-0.2395image
ENSG00000090054.12,SPTLC1UCSGSK.650394EAG2.4381e-02-0.3799image
ENSG00000090054.12,SPTLC1UVMCCT007093EAG9.2340e-03-0.5004image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType